Document is current
Any future updates will be listed below
-
Authors
Brand, Eva https://orcid.org/0009-0004-3243-5508
Linhart, Aleš
Deegan, Patrick
Jurcut, Ruxandra
Pisani, Antonio
Torra, Roser
Feldt-Rasmussen, Ulla
-
Funding
Funding for this research was provided by:
Universitätsklinikum Münster
- License Information
-
More Information
Article History
Received: 28 March 2024
Accepted: 6 December 2024
First Online: 7 January 2025
Declarations
:
: All procedures followed for the patient interviews were in accordance with the Helsinki Declaration 1975. Informed consent was obtained from all patients interviewed.
: Not applicable.
: Eva Brand received research grants and speaker/consulting honoraria from Amicus Therapeutics, Chiesi, Sanofi, and Takeda. Aleš Linhart received speakers and consulting fees from Amicus Therapeutics, Chiesi, Sanofi, and Takeda. Patrick Deegan received speaker/consulting honoraria from Amicus Therapeutics, Chiesi, Sanofi and Takeda, and research grants from Sanofi and Takeda. Ruxandra Jurcut received non-restrictive educational grants and speaker fees from Genesis Pharma (representing Amicus), Sanofi, and Takeda. Antonio Pisani received travel expenses and grants from Amicus, Sanofi, Chiesi-Protalix and Takeda-Shire. Roser Torra received speaker/consulting honoraria from Amicus Therapeutics, Chiesi, Sanofi Genzyme, and Takeda. Ulla Feldt-Rasmussen received unrestricted educational grants and speaker/consulting honoraria from Amicus Therapeutics, Chiesi, Freeline, Sanofi, and Takeda; Ulla Feldt-Rasmussen also received a research salary that was supported by a grant from Kirsten and Freddy Johansen’s Fund.
